QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia.

Vebeglogene autotemcel is under clinical development by Lantu Biopharma and currently in Phase II for Beta Thalassaemia.

QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.

CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Refractory Multiple Myeloma.

ND02 is under clinical development by HK inno.N and currently in Phase II for Glaucoma. According to GlobalData, Phase II drugs for Glaucoma have a 39% phase transition success rate (PTSR) indication ...

Zofin is under clinical development by ZEO ScientifiX and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

CYTO-102 is under clinical development by CytoImmune Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

Not Disclosed Neuroscience and Pain 2 is under clinical development by Evotec and currently in Phase I for Unspecified Neurologic Disorders.

PrimePro is under clinical development by Thomas Advanced Medical and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

R3R-01 is under development for the treatment of Alport syndrome, diabetic kidney disease and focal segmental glomerulosclerosis. It is administered through oral route.

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Diffuse Large B-Cell Lymphoma.

IMM-1-104 is under clinical development by Immuneering and currently in Phase II for Non-Small Cell Lung Cancer.